Most recently, the combination of antibodies against PD1 (nivolumab) and CTLA4 (ipilimumab) was approved for treatment of HCC patients, who previously received sorafenib, with an overall response rate of 33% (12). The gene discussed is CTLA4; the disease is hepatocellular carcinoma.